This analysis of the National Institutes of Health-funded Bypassing the Blues trial was published online today in General Hospital Psychiatry. While previous research showed this collaborative care model to be effective for treating post-CABG depression, the latest study establishes the "business case" to policy makers and insurers for widespread adoption, said Bruce L. Rollman, M.D., M.P.H., professor of medicine, psychiatry, and clinical and translational science at the University of Pittsburgh School of Medicine and principal investigator of the trial.
"One of the holy grails in mental health services research is to demonstrate that treating a common mental health condition such as depression is not only effective and cost-effective, but is also cost-saving. This is the first trial to demonstrate all three outcomes," said Dr. Rollman. "We now know that screening for and then providing effective depression treatment to medically complex patients with cardiovascular disease is very likely to pay for itself." A recent American Heart Association science advisory already recommends routine screening and treatment of depression in patients with cardiac disease, he noted.
Researchers examined Medicare and private medical insurance claims data for 189 trial participants. After incorporating the $460 average cost to deliver the intervention that included nurse and supervising physician time, patients randomly assigned to the intervention had $2,068 lower median claims costs at one year after bypass surgery compared to those who received their doctors' usual care ($16,126 vs. $18,194). The intervention was also highly cost-effective, producing more quality-adjusted life-years (QALY), a measure analysts use to determine the value of different medical actions, while significantly lowering medical claims costs by $9,889 per additional QALY generated, a first for a collaborative care strategy for treating depression in any patient population.
About 400,000 CABG surgeries are performed annually in the U.S., and studies indicate approximately one in five patients who undergo the procedure experience clinical depression. Extending this $2,068 savings to all depressed post-CABG patients has the potential to save over $165 million in medical claims in the first year following surgery, said Dr. Rollman.
The collaborative care model involves care managers who follow an evidence-based treatment protocol under the supervision of a primary care physician. The team systematically contacts patients to monitor their mood symptoms and recommends appropriate adjustments in treatment. Although team-based collaborative care for depression has yet to be widely adopted, it is increasingly being provided by integrated health care systems through "patient-centered medical homes" supported by payment reforms under the Affordable Care Act.
Collaborators on this study include Julie M. Donohue, Ph.D., Bea Herbeck Belnap, Ph.D., Aiju Men, M.S., Fanyin He, Ph.D., Mark S. Roberts, M.P.P., M.D., andCharles F. Reynolds III, M.D., all of the University of Pittsburgh, and Herbert Schulberg, Ph.D., of Weill Cornell Medical College.
The research was supported by the Fine Foundation and by The National Heart Lung and Blood Institute, part of the National Institutes of Health grant number R01HL70000.
For more information about the Bypassing the Blues trial, visit:www.bypassingtheblues.pitt.edu
# # #
About the University of Pittsburgh School of Medicine
As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In rankings recently released by the National Science Foundation, Pitt ranked fifth among all American universities in total federal science and engineering research and development support.
Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see www.medschool.pitt.edu.
For ad rates, call Mike McCurdy at 877-634-9180 or email at tvmike13@HealthNewsDigest.com We have over 7,000 journalists who are subscribers.